Introduction {#Sec1}
============

Metabolic syndrome (MetS) is an intriguing entity, because it includes potentially reversible risk factors and is associated, at least in middle-aged populations, with several adverse outcomes, including cardiovascular and cerebrovascular morbidity and mortality \[[@CR1]\].

On the other hand, several studies have indicated that sleep duration and architecture are associated with obesity, diabetes, hypertension, cardiovascular disease, and in turn, with MetS \[[@CR2]--[@CR4]\]. Several data indicate an association between the characteristics of sleep and the risk of cardiovascular events. For instance, the duration of sleep has been associated with left ventricular function and structure \[[@CR5]\], while sleep disruption has been linked with atrial fibrillation \[[@CR6]\]. The quality of sleep maintains its prognostic value even in the oldest age. In fact, in oldest subjects a self-rated poor quality of sleep is associated with reduced survival \[[@CR7]\], and an objective measure of sleep quality has been associated with physical performance \[[@CR8]\].

In a meta-analysis including over 75,000 participants the probability of MetS increased by 16% for a sleep duration below 8 h \[[@CR9]\], and in a prospective cohort study sleep restriction resulted a risk factor for incident MetS \[[@CR10]\]. Indeed, sleep plays a key role in maintaining circadian rhythm and metabolic and hormonal homeostasis \[[@CR11]\]. Not surprisingly, the impairment of quantity and quality of sleep represents a risk factors for cardio-metabolic diseases, depression and cognitive impairment \[[@CR12]\]. Therefore, ensuring adequate sleep quality is essential for improving quality of life and reducing mortality \[[@CR13], [@CR14]\]. On the other hand, MetS has been proven an independent risk factor for respiratory disorders, that in turn affect quality of sleep \[[@CR4]\]. The potential association of MetS with sleep quality is further confounded by several factors, including subclinical inflammation and nutritional status.

Indeed, MetS has not so far been associated with clinically meaningful outcomes in the very old, and in some studies it has even been associated with positive outcomes, including better cognitive functioning, higher hemoglobin levels, quality of life, and functional ability \[[@CR15]--[@CR19]\]. Specifically, an association between poor sleep quality and MetS has been reported in younger and middle-aged adults; however, data are lacking regarding older and oldest populations \[[@CR2], [@CR3]\]. Thus, the aims of the present study were to assess the association, if any, of MetS with quality of sleep in a cohort of oldest subjects, and whether the direction of such an association is the same observed in younger populations.

Methods {#Sec2}
=======

Population {#Sec3}
----------

This study is based upon data from the "Mugello Study", a survey of nonagenarians (i.e., subjects aged 90+) living in the Mugello area, north-eastward of Florence, in Tuscany, Italy. Details on aims, design and methods of the study are reported elsewhere \[[@CR20]\]. Briefly, 475 unselected nonagenarians underwent structured interview and medical visit at home, along with comprehensive instrumental assessment and collection of blood samples. The Mugello Study protocol, which complied with the principles of the Declaration of Helsinki on clinical research involving human beings, was approved by the Institutional Review Board; participants, or their proxies, signed the informed consent form.

Data for the present study were available for 343 subjects, as we excluded from the original sample 91 participants with diagnosis of dementia, and 41 because of missing data for the study variables.

Sleep quality {#Sec4}
-------------

The Pittsburgh Sleep Quality Index (PSQI) was adopted to test the quality and pattern of sleep over the preceding 4 weeks \[[@CR21]\]. The PSQI differentiated "poor" from "good" sleep by measuring the following seven areas: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of hypnotics, and daytime dysfunction. Scoring was based on a 0--3 Likert scale, and the sum of scores for these seven components yielded a global score ranging 0 to 21. A total score ≥ 5 represents inappropriate sleep quality, higher scores indicating lower quality of sleep. Using a cut-off score of 5, the PSQI has a sensitivity of 89.6% and specificity of 86.5% for identifying cases with a sleep disorder \[[@CR22], [@CR23]\].

Metabolic syndrome {#Sec5}
------------------

MetS was defined according to the National Cholesterol Education Program's ATP-III criteria, adding use of hypolipemic, hypoglycemic, and antihypertensive medications as in several previous epidemiological studies \[[@CR24]\]. The diagnosis of the MetS was defined by the presence of three or more of the following features: waist circumference \> 88 cm in women and \> 102 cm in men; fasting serum triglycerides ≥ 150 mg/dL; serum HDL \< 50 mg/dL in women and \< 40 mg/dL in men, or use of hypolipemic drugs; blood pressure ≥ 130/85 mmHg, or use of antihypertensive drugs; fasting blood glucose levels ≥ 110 mg/dL, or use of hypoglycaemic drugs.

Covariates {#Sec6}
----------

Education was expressed as years of school attendance. Comorbidity was quantified using the Charlson score \[[@CR25]\]. Body Mass Index (BMI) was calculated as weight (kg) divided by height squared (m^2^). Functional ability was estimated using the Katz' activities of daily living (ADLs) \[[@CR26]\] and the Lawton and Brody scale for instrumental activities of daily living (IADLs) \[[@CR27]\]. Disability in the ADLs was defined as need of assistance for performing two or more ADLs. The reason for not choosing a single-point decline is that impairment in two ADLs is less likely to capture physiological fluctuations in functional performance. Impairment in IADL function was identified by a score \< 7; this higher cut-off level is generally adopted to avoid a "floor effect". Cognition was assessed using the Mini Mental State Examination \[[@CR28]\]. Adherence to a Mediterranean-style diet was computed using the Mediterranean Diet Score \[[@CR29]\]. Physical performance was assessed using the Short Physical Performance Battery, which includes three tests of physical function: balance, gait speed, and chair stands \[[@CR30]\]. Drugs were coded according to the Anatomical Therapeutic and Chemical codes/Defined Daily Dose \[[@CR31]\]. Diagnoses were coded according to the International Classification of Diseases, ninth edition, Clinical Modification codes \[[@CR32]\]. Glomerular Filtration Rate was estimated using the Cockcroft-Gault equation.

Statistical analysis {#Sec7}
--------------------

Statistical analyses were performed using SPSS for Mac 20.0, and R-3.5.3. Differences were considered significant at the P \< .050 level. Data of continuous variables are presented as mean values ± standard deviation (SD). Median and inter-quartile ranges were provided for non-normally distributed variables. Analysis of variance (ANOVA) for normally distributed variables was performed according to good quality of sleep (i.e. PSQI \< 5), and MetS; otherwise, the nonparametric Mann--Whitney U test was adopted. The two-tailed Fisher exact test was used for dichotomous variables. The covariates to be included into multivariable analyses were chosen as explanatory according to available evidence from the electronic databases of PubMed (MEDLINE) and Cochrane Library, and based upon biological plausibility. All the variables associated with either the PSQI or the MetS were included among the covariates in multivariable analyses \[[@CR33]\].

Multivariable linear regression analysis was adopted to estimate the association of PSQI with age, sex, MetS, and all those variables which differed significantly (P \< .05) in univariable analyses (Tables [1](#Tab1){ref-type="table"}, and [2](#Tab2){ref-type="table"}).Table 1Characteristics of 343 participants according to a Pittsburgh Sleep Quality Assessment index (PSQI) \< 5 (indicating good quality of sleep)Participants with PSQI \< 5 (n = 83)Participants with PSQI ≥ 5 (n = 260)PN (%), mean (SD) or median (interquartile range) \[traditional units\] Demographics and lifestyle habits  Age (years)92 (3)93 (3).455  Sex (female)54 (65)182 (70).816  Education (years)5 (3--5)4 (3--5).404  Alcohol consumption (mL/day)4.5 (.9)4.7 (.7).169  Smoking (total lifetime pack years)3650 (1825--7300)3650 (1460--7300).676  Mediterranean diet score34.9 (2.9)34.1 (3.8).081  Living in nursing home8 (10)21 (8).653 Medications  ACE-inhibitors31 (37)93 (36).896  Diuretics43 (52)137 (53).900  Beta-blockers16 (20)37 (14).293  Platelet antiaggregants46 (55)90 (35).001  Benzodiazepines7 (8)56 (22).006  Antidepressants14 (17)47 (18).870  Antipsychotics4 (5)22 (8).346  Analgesics or oppioids4 (5)22 (8).346  Non steroidal anti-inflammatory drugs7 (8)40 (15).142  Corticosteroids1 (1)16 (6).083  Antihistaminics01 (1).999 Comorbid conditions  Charlson comorbidity Index1 (0--3)1 (0--4).440  Metabolic syndrome28 (34)47 (18).004  Heart failure12 (15)67 (27).035  Chronic pulmonary disease10 (13)38 (15).715  Stroke or cerebrovascular disease12 (15)55 (22).203  Peripheral arterial disease16 (20)50 (20).999  Connectivities3 (4)5 (2).409  Hepatic disease4 (5)10 (4).751  Depression1 (1)15 (6).132 Physical and cognitive performance  Mini mental state examination20.1 (9.2)21.9 (6.7).052  Disability in BADL33 (40)129 (49).165  Disability in IADL69 (83)225 (86).472  Short physical performance battery7 (3)6 (3).225  Body mass index (Kg/m^2^)25.5 (4.2)25.5 (4.9).972 Biohumoral parameters  Glomerular filtration rate (mL/min)39.5 (16.7)40.1 (16.9).800  Hemoglobin (g/L) \[g/dL)\]131 (17) \[13.1 (1.7)\]128 (15) \[12.8 (1.5)\].187  Total serum proteins (g/dL) \[g/L\]65 (7) \[6.5 (.7)\]65 (6) \[6.5 (.6)\].536  Albumin (proportion of 1) \[%\].56 (.05) \[55.6 (4.6)\].57 (.04) \[57.2 (4.4)\].013  C-reactive protein (nmol/L) \[mg/L\]3.43 (1.71--6.95) \[.36 (.18--.73)\]3.90 (1.62--7.52) \[.41 (.17--.79)\].347Table 2Characteristics of 343 participants according to the presence of metabolic syndromeParticipants with metabolic syndrome (n = 75)Participants without metabolic syndrome (n = 268)PN (%), mean (SD) or median (interquartile range) \[traditional units\] Demographics and lifestyle habits  Age (years)92 (3)93 (3).028  Sex (female)59 (79)177 (66).048  Education (years)5 (3--5)5 (3--6).776  Alcohol consumption (mL/day)4.7 (.7)4.6 (.8).769  Smoking (total lifetime pack years)4867 (3650--7300)3650 (1217--7300).071  Mediterranean diet score34.0 (4.0)34.3 (3.5).526  Living in nursing home7 (9)22 (8).814 Medications  ACE-inhibitors35 (47)89 (33).041  Diuretics39 (52)141 (53).999  Beta-blockers19 (26)34 (13).010  Platelet antiaggregants32 (43)104 (39).594  Benzodiazepines9 (12)54 (20).129  Antidepressants19 (25)42 (16).062  Antipsychotics5 (7)21 (8).999  Analgesics or oppioids6 (8)20 (7).810  Non steroidal anti-inflammatory drugs13 (17)34 (13).343  Corticosteroids4 (5)13 (5).772  Antihistaminics0 (0)1 (.4).999 Comorbid conditions  Charlson comorbidity Index1 (0--6)1 (0--3).035  Heart failure13 (18)66 (26).166  Chronic pulmonary disease10 (14)38 (15).853  Stroke or cerebrovascular disease16 (22)51 (20).745  Peripheral arterial disease13 (18)53 (21).662  Connectivities1 (1)7 (3).689  Hepatic disease3 (4)2 (1).077  Depression2 (3)14 (5).538 Physical and cognitive performance  Mini mental state examination21.2 (8.0)21.6 (7.2).745  Disability in BADL34 (45)127 (47).794  Disability in IADL67 (89)227 (85).356  Short physical performance battery6 (2)6 (3).676  Body mass index (kg/m^2^)27.4 (4.1)24.9 (4.8)\<.0001  Pittsburgh sleep quality assessment6 (4)8 (4).007 Biohumoral parameters  Glomerular filtration rate (mL/min)37.2 (16.0)40.0 (17.0).121  Hemoglobin (g/L) \[g/dL\]124 (16) \[12.4 (1.6)\]130 (15) \[13.0 (1.5)\].002  Total serum proteins (g/dL) \[g/L\]64 (7) \[6.4 (.7)\]65 (6) \[6.5 (.6)\].371  Albumin (proportion of 1) \[%\].57 (.05) \[56.9 (4.8)\].58 (.04) \[56.7 (4.4)\].811  C-reactive protein (nmol/L) \[mg/L\]3.43 (1.52--7.43) \[.44 (.16--.78)\]2.67 (1.43--6.67) \[.28 (.15--.70)\].302

Multivariable logistic regression analysis was adopted to estimate the association of a good quality of sleep (i.e. PSQI \< 5) with age, sex, MetS, and all those variables which differed significantly (P \< .05) in univariable analyses (Tables [1](#Tab1){ref-type="table"}, and [2](#Tab2){ref-type="table"}); the BMI was not entered because of its collinearity with MetS. The same set of covariates was also entered in logistic regression having a PSQI below the median value as dependent variable. To rule out any role of body size, logistic models were analyzed after the insertion of the BMI instead of MetS. Also, the same set of covariates was analyzed after the inclusion of the Mini Mental State Examination score in the multivariable model, to take into account the role of cognition in the association between sleep and MetS. The same multivariable regression models were analyzed after stratifying for sex. Analysis of the interaction term sex\*MetS was performed to assess the role of gender in the association between MetS and quality of sleep.

Eventually, the multivariable logistic models were analyzed after entering the single items of Mets, as well as the number of MetS components.

Collinearity diagnostics estimated by the Variance Inflation Factor indicated no collinearity between the covariates entered into the models (all VIF values \< 2); also, test of goodness of fit performed by the Hosmer and Lemeshow Test indicated a good fit of the models (all P values \> .050).

Eventually, generalized additive model (GAM) analysis was performed to rule out any curvilinear relationship of metabolic syndrome with quality of sleep.

Based upon available data, \[[@CR34]\] analysis by G\*Power indicated that a sample of 302 elderly patients would allow over 80% power for detecting a 1.9 OR in logistic regression analysis (α = .05) having a good quality of sleep as the dependent outcome.

Results {#Sec8}
=======

In our population, good quality of sleep was reported by 83 (24%) subjects, while 178 (52%) subjects had a PSQI score ≤ the median value; the median PSQI was 7 (5--10). MetS was diagnosed in 75 (22%) participants. Participants with MetS had a significantly lower PSQI than subjects without MetS (6 (3--10) vs 8 (5--11); P = .005).

The main characteristics of the population according to a PSQI \< 5 are depicted in Table [1](#Tab1){ref-type="table"}. Specifically, as compared with controls, they had less prevalent diagnosis of heart failure, reported a less prevalent use of benzodiazepines, and a more prevalent use of antiplatelets; also, they showed lower serum albumin levels; eventually, participants with a good quality of sleep had a more prevalent diagnosis of MetS.

The main characteristics of the population according to the presence of metabolic syndrome are depicted in Table [2](#Tab2){ref-type="table"}. Specifically, as compared with controls, they were more likely younger females with higher body mass index; they had an higher Charlson scores; also, they reported a more prevalent use of ACE-inhibitors and beta-blockers; they showed lower hemoglobin levels; eventually, participants with MetS reported a lower PSQI score, as compared with controls.

In linear regression, PSQI was inversely associated with MetS in the crude model (B = -1.33; 95% CI − 2.28 to − .37; P = .007), after adjusting for age and sex (B = − 1.36; 95% CI − 2.33 to − .39; P = .006), and in the multivariable model (B = − 1.04; 95% CI − 2.06 to − .03; P = .044; Table [3](#Tab3){ref-type="table"}).Table 3Association of the Pittsburgh sleep quality assessment index (PSQI) with the variables of interestLinear regression modelPSQI as a continuous variableB95% CIPAge (each year)− .05− .20 to .09.467Sex (female).22− .77 to 1.22.658Benzodiazepines1.44.26 to 2.61.017Platelet antiaggregants− 1.84− 2.76 to − .92.000ACE-inhibitors− .14− 1.25 to .97.800Beta-blockers.27− 1.02 to 1.56.683Charlson comorbidity Index.07− .13 to .27.495Heart failure.92− .16 to 2.00.095Albumin (proportion of 1) \[%\]− .38− 1.11 to .34.296Hemoglobin (g/L) \[g/dL\]− .12− .42 to .19.443Metabolic syndrome− 1.04− 2.06 to − .03.044Logistic regression modelPSQI \< 5OR95% CIPAge (each year)1.01.91 to 1.12.856Sex (female)1.03.54 to 1.99.920Benzodiazepines.31.12 to .80.015Platelet antiaggregants2.251.22 to 4.17.010ACE-inhibitors.88.47 to 1.67.698Beta-blockers1.02.46 to 2.29.953Charlson comorbidity Index.92.80 to 1.07.276Heart failure.49.23 to 1.08.076Albumin (proportion of 1) \[%\].91.85 to .98.012Hemoglobin (g/L) \[g/dL\]1.17.95 to 1.44.139Metabolic syndrome2.521.26 to 5.02.009Logistic regression modelPSQI ≤ 7OR95% CIPAge (each year).97.89 to 1.06.536Sex (female).60.33 to 1.06.079Benzodiazepines.40.20 to .81.011Platelet antiaggregants1.851.08 to 3.16.025ACE-inhibitors1.811.04 to 3.15.037Beta-blockers.93.44 to 1.94.839Charlson comorbidity Index.95.84 to 1.07.424Heart failure.89.47 to 1.66.705Albumin (proportion of 1) \[%\].95.89 to 1.04.069Hemoglobin (g/L) \[g/dL\]1.08.90 to 1.30.413Metabolic syndrome2.111.11 to 3.40.022All the covariates were entered simultaneously into the regression models. The model included all the variables which differed significantly (P \< .050) in univariable analyses in Tables [1](#Tab1){ref-type="table"}, and [2](#Tab2){ref-type="table"}

In logistic regression a good quality of sleep (i.e. PSQI \< 5) was associated with MetS in the crude model (OR = 2.31; 95% CI 1.33--4.01; P = .003), after adjusting for age and sex (OR = 2.40; 95% CI 1.36--4.23; P = .003), as well as in the multivariable model (OR = 2.52; 95% CI 1.26--5.02; P = .009; Table [3](#Tab3){ref-type="table"}).

Likewise, MetS was associated with increased probability of a PSQI below the median (i.e. PSQI ≤ 7) in the crude model (OR = 2.19; 95% CI 1.28--3.74), after adjusting for age and sex (OR = 2.26; 95% CI 1.30--3.91; P = .004), and in the multivariable model (OR = 2.11; 95% CI 1.1--3.40, P = .022 Table [3](#Tab3){ref-type="table"}).

In contrast, no association was found (B = .01; 95% CI − .08 to .11; P = .772 for PSQI as a continuous variable; OR = 1.01; 95% CI .95--1.07; P = .847 for PSQI \< 5, and OR = 1.01; 95% CI .95--1.06; P = .912 for PSQI ≤ 7) for BMI when it was entered instead of MetS in the multivariable models.

Furthermore, after adjusting for cognitive performance, although in multivariable linear model metabolic syndrome was not significantly associated with the whole spectrum of the PSQI (B = − .86; 95% CI − 1.86 to.14; P = .092), in logistic multivariable models MetS was associated with a good quality of sleep (OR = 2.42; 95% CI 1.20--4.88, P = .014) and with PSQI below the median (OR = 2.06; 95% CI 1.09--3.92, P = .027).

When the multivariable regression models were analyzed after stratifying for sex, MetS was statistically associated with the PSQI score (B = − 2.66, 95% CI − 4.51 to .81; P = .005), with a good quality of sleep (OR = 4.64; 95% CI 1.20--18.00, P = .026), and with a PSQI below the median (OR = 12.93; 95% CI 2.26--23.98, P = .004) in men; in women MetS was not significantly associated with the PSQI score (B − .72, 95% CI − 1.94 to .50; P = .247); however a significant association was found of MetS with a good quality of sleep (OR = 2.70; 95% CI 1.22--6.01, P = .015), and with a PSQI below the median (OR = 2.09; 95% CI 1.02--4.25, P = .043). Analysis of the interaction term confirmed that the association between quality of sleep and MetS was not affected by sex (P = .215 for PSQI; P = . 532 for PSQI \< 5; P = .724 for PSQI below the median).

None of the single components of MetS was significantly associated with a good quality of sleep or with a PSQI below the median (Table [4](#Tab4){ref-type="table"}), also after stratifying for sex. However, an increasing number of MetS components was associated with increasing probability of good quality of sleep (P for linear trend = .005), as well as of a PSQI ≤ 7 (P for linear trend = .024), after adjusting.Table 4Association of Pittsburgh sleep quality assessment index (PSQI) with the single components of MetSLinear regression modelPSQI as a continuous variableB95% CIPAbdominal obesity− .24− 1.30 to .81.651Hypertriglyceridemia− 1.21− 2.55 to .12.074Low HDL − cholesterol.11− 1.09 to 1.31.855High blood pressure.07− 1.05 to 1.19901High fasting blood glucose− .23− 1.43 to .96.700Logistic regression modelPSQI \< 5OR95% CIPAbdominal obesity1.36.72 to 2.57.339Hypertriglyceridemia1.98.94 to 4.15.071Low HDL-cholesterol1.02.50 to 2.07.964High blood pressure.78.41 to 1.48.451High fasting blood glucose1.35.67 to 2.71.403Logistic regression modelPSQI ≤ 7OR95% CIPAbdominal obesity1.41.81 to 2.43.222Hypertriglyceridemia1.60.79 to 3.22.190Low HDL-cholesterol.92.49 to 1.71.791High blood pressure1.53.88 to 2.67.132High fasting blood glucose1.46.78 to 2.72.239All the covariates were entered simultaneously into the regression models. The model included all the variables which differed significantly (P \< .050) in univariable analyses in Tables [1](#Tab1){ref-type="table"}, and [2](#Tab2){ref-type="table"} (i.e. age, sex, use of benzodiazepines, platelet antiaggregants, ACE-inhibitors, and beta-blockers, diagnosis of heart failure, Charlson comorbidity score index, albumin, and hemoglobin levels)

Results of GAM analysis were summarized in Additional file [1](#MOESM1){ref-type="media"}: Table S1; overall, there was no smoothing function suggestive of nonlinear association between MetS and PSQI; however, when the single components of MetS were analyzed, there was a nonsignificant smoothed association of low HDL-cholesterol and hypertension with PSQI (Additional file [1](#MOESM1){ref-type="media"}: Table S1).

Discussion {#Sec9}
==========

Our results indicate that MetS was independently associated with a better quality of sleep in our sample of community-dwelling oldest subjects; the syndrome in itself, rather than its individual components, seemed to be associated with sleep quality, with a linear association between increasing number of items and increasing probability of a better sleep quality. Our results confirmed data indicating that MetS and sleep seem associated and, in particular, lower night sleep hours are related to higher risk of development of MetS. This is particular shown for young and middle-aged people \[[@CR35]\].

This finding is intriguing, because it is at variance with the common opinion that MetS might represent either a consequence or a cause of disturbed sleep. A possible explanation for our contrasting results is that previous studies which analyzed the correlation between MetS and sleep included much younger subjects \[[@CR2]--[@CR4], [@CR9]\]. Of notice, MetS has been associated with better cognitive performance \[[@CR16]\] and quality of life among subjects aged 80+ \[[@CR17]\]; also, it has been linked with better functional ability in participants aged 75+ \[[@CR18]\], while it is not a risk factor for reduced survival in the elderly, as in younger subjects \[[@CR36]\]. Indeed, an association of MetS with a better quality of sleep should be expected in the light of these findings.

Interestingly, Qian and colleagues showed this relationship in relatively old adults \[[@CR37]\]. Actually, they evaluated subjects aged at least 60 years old and found that the lowest risk of MetS is present in people who sleep for at least 7 h in the night. Additionally, even the day portion of sleeping is important. In fact the daytime napping may represent a non-functional sleep and increase the risk of MetS \[[@CR37]\]. However, in comparison to our work, in Quian's study people with a wide age range were considered and this should explain the difference with our results. Other studies found similar results but, usually, the age range is very variable and a substantial rarity of specific results for healthy nonagerians is visible \[[@CR9], [@CR38]\]. These last considerations is supported by the findings of other studies, where a wider assessment of the relationship with the age was performed. Stefani and colleagues evaluated Korean people and found that the very low sleep duration was correlated with MetS in middle-age men and they conclude that age and sex change the relationship between sleep duration and MetS \[[@CR39]\]. This strengthens the necessary division of the population, on the basis of the age, to adequately perform studies assessing metabolic condition.

This counterintuitive behavior of MetS might belong to so-called "reverse epidemiology", according to which factors improving short-term survival and/or well-being, albeit reducing long-term survival, are associated with decreased mortality and event rates among subjects with reduced life expectancy \[[@CR40]\]. Thus, established risk factors in general populations yield paradoxically opposite predictive patterns in populations characterized by "frailty". In these subjects the components of MetS reflect the absence of more powerful risk factors, including malnutrition, that most commonly, and in a shorter term, might affect health status and survival \[[@CR40]\]. In this setting, our finding of an association between higher serum albumin levels and better quality of sleep confirm the role of a better nutritional status on the maintenance of sleep quality. Of notice, our results confirm a greater prevalence of heart failure in subjects with worse quality of sleep; obesity, increased serum cholesterol levels and higher blood pressure have been associated with reduced morbidity and mortality in subjects with frailty due to heart failure or end-stage renal disease, as well as in older subjects \[[@CR41]\]. Also, the "obesity paradox" might allow to interprete our results. In fact, obesity has been associated with a better quality of life, and quality of sleep is a part of quality of life. Also, higher waist circunference has been associated with lower incidence of disability in people aged 90+ \[[@CR42]\]. People with low weight may suffer from malnutrition, which makes them more susceptible to disease and disability \[[@CR43]\], and malnutrition has been associated with poorer quality of sleep \[[@CR44]\]. Moreover, quality of sleep is inversely related with sarcopenia and frailty \[[@CR45]\].

Also, poor sleep quality could be a consequence of obstructive sleep apnea, which may derive from MetS \[[@CR46]\]; thus, sleep apnea would be a mediator of this association, at least in younger population, while it has been showed that in an aged animal model, chronic intermittent hypoxia does not alter carotid body responses, catecholamine‐related parameters or redox status, and does not cause hypertension, thus authors argue that age affords protection to harmful effects produced by chronic intermittent hypoxia \[[@CR47]\].

Furthermore, we have to consider that subjects who "survived" over 90 years despite MetS were probably less susceptible to its cardiovascular effects. Also, inflammation and oxidative stress are considered other mechanisms which link poor sleep with cardiometabolic risk profile in adults. Indeed, in sleep disordered populations elevated levels of inflammation and oxidative stress are common features \[[@CR48]\]. However, this observation has not been confirmed in our population, as C Reactive Protein levels were not associated with quality of sleep. Eventually, it has been hypothesized that the common pathophysiological pathway of MetS and poor sleep is the hyperactivation of the hypothalamic-pituitary- adrenal axis \[[@CR49]\]; indeed, such hyperactivation might account for an increased cardiovascular risk. However, such hyperactivation has been found in young subjects, but not confirmed in the elderly \[[@CR50]\]. The association of good quality of sleep with MetS did not differ between men and women, as confirmed by the lack of interaction between MetS and sex.

Strengths and limitations {#Sec10}
-------------------------

The present study has some limitations. First, due to its cross-sectional design this study does not allow to ascertain any cause-effect relationship. Second, sleep was evaluated using the self-reported PSQI questionnaire, while no objective measure of sleep disturbance (e.g. polysomnography) was performed; however, subjective sleep quality represents a good prognostic marker even in very old populations \[[@CR7]\]; in addition, there was lack of information about other indirect aspects of sleep quality, such as daytime sleepiness, which is explored by the Epworth Sleepness Scale. Eventually, only the overall score was available for the present analyses.

This study has also some strengths. First, to our knowledge this is the first study that analyzed the association between MetS and sleep in a population on nonagenarians. Second, we enrolled a community-dwelling population, with extensive information regarding risk factors, comorbid conditions, and objective parameters. Finally, as it included approximately 65% of nonagenarians living in the Mugello area, this sample seems to be fairly representative.

Conclusion {#Sec11}
==========

In oldest subjects, MetS might be significantly associated with greater quality of sleep. Results of the present study might query the opportunity of treating MetS to improve quality of sleep or, conversely, of increasing sleep to reduce MetS prevalence in very old subjects. Together with other counterintuitive associations in very old populations, our results might caution against considering the evidence pertaining to adults and "young elderly" also valid for the "old old". As the "old old" segment of general populations is dramatically rising, and not only in western countries, epidemiological surveys should pay more attention to this population, and clinical practice should capitalize on geriatric epidemiological research. Finally, longitudinal studies are still needed to confirm our findings.
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###### 

**Additional file 1: Table S1.** Results of the generalized additive model having the metabolic syndrome and its single components as the dependent variable and quality of sleep as the independent variable.

MetS

:   Metabolic syndrome

PSQI

:   Pittsburgh sleep quality assessment index
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:   Body mass index

ADLs

:   Activities of daily living

IADLs

:   Instrumental activities of daily living
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